Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Maximilian Stahl, M.D.

Title
Institution
Department
Address
Phone
Profile Picture

Biography
Hannover Medical School, Hannover MD06/2013Medical School
Yale School of Medicine , New Haven06/2017Internal Medicine Internship/Residency
Yale School of Medicine , New Haven06/2018Chief Residency
Memorial Sloan Kettering Cancer Center, New York06/2021Hematology/Oncology Fellowship
2017 - 2018
HONORS Award American Society of Hematology (ASH)
2020 - 2021
Young Investigator Award, American Society of Clinical Oncology (ASCO) Conquer Cancer Foundation
2006 - 2013
Scholarship, German National Academic Foundation (Studienstiftung)

Overview
Dr. Stahl graduated from Hannover Medical School in Hannover, Germany. He received his internal medicine residency training at the Yale School of Medicine where he also served as a chief medical resident. He then completed his Hematology and Oncology fellowship training at the Memorial Sloan Kettering Cancer Center in New York City. He is currently a member of the Adult Leukemia Group at Dana-Farber Cancer Institute and also a member of the faculty at Harvard Medical School. His interest is in clinical and translational research in myeloid malignancies with a focus on early phase clinical trial development in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Badar T, Atallah E, Shallis RM, Goldberg AD, Patel A, Abaza Y, Bewersdorf JP, Saliba AN, Correia GSC, Murthy G, Duvall A, Burkart M, Stahl M, Liu Y, Dinner S, Palmisiano N, Litzow MR, Foran JM. Outcomes of TP53-mutated AML with evolving frontline therapies: Impact of allogeneic stem cell transplantation on survival. Am J Hematol. 2022 Mar 26. PMID: 35338673.
    Citations:    Fields:    
  2. Shimony S, Stone RM, Stahl M. Venetoclax combination therapy in acute myeloid leukemia and myelodysplastic syndromes. Curr Opin Hematol. 2022 Mar 01; 29(2):63-73. PMID: 34966123.
    Citations: 1     Fields:    
  3. Bewersdorf JP, Tallman MS, Stahl M. Maintenance therapies in acute myeloid leukemia: the renaissance of an old therapeutic concept. Curr Opin Oncol. 2021 11 01; 33(6):658-669. PMID: 34341323.
    Citations:    Fields:    Translation:Humans
  4. King AC, Weis TM, Derkach A, Ball S, Pandey M, Mauro MJ, Goldberg AD, Stahl M, Famulare C, Tallman MS, Wang ES, Kuykendall AT, Rampal RK. Multicenter evaluation of efficacy and toxicity of venetoclax-based combinations in patients with accelerated and blast phase myeloproliferative neoplasms. Am J Hematol. 2022 01 01; 97(1):E7-E10. PMID: 34674293.
    Citations:    Fields:    Translation:Humans
  5. Bewersdorf JP, Stone RM, Tallman MS, Stahl M. Does the conventional cytogenetic risk profile still matter for prediction of venetoclax based treatment outcomes in AML? Leuk Lymphoma. 2021 12; 62(14):3318-3319. PMID: 34587866.
    Citations:    Fields:    
  6. Bewersdorf JP, Allen C, Mirza AS, Grimshaw AA, Giri S, Podoltsev NA, Gowda L, Cho C, Tallman MS, Zeidan AM, Stahl M. Hypomethylating Agents and FLT3 Inhibitors As Maintenance Treatment for Acute Myeloid Leukemia and Myelodysplastic Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation-A Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 12; 27(12):997.e1-997.e11. PMID: 34551341.
    Citations: 1     Fields:    Translation:Humans
  7. Stahl M, Tallman MS, Goldberg AD. Measurable residual disease negativity in acute myeloid leukemia: the destination may matter more than the journey. Leuk Lymphoma. 2021 09; 62(9):2050-2051. PMID: 34519611.
    Citations:    Fields:    Translation:Humans
  8. Bewersdorf JP, Derkach A, Gowda L, Menghrajani K, DeWolf S, Ruiz JD, Ponce DM, Shaffer BC, Tamari R, Young JW, Jakubowski AA, Gyurkocza B, Chan A, Xiao W, Glass J, King AC, Cai SF, Daniyan A, Famulare C, Cuello BM, Podoltsev NA, Roshal M, Giralt S, Perales MA, Seropian S, Cho C, Zeidan AM, Prebet T, Stein EM, Tallman MS, Goldberg AD, Stahl M. Venetoclax-based combinations in AML and high-risk MDS prior to and following allogeneic hematopoietic cell transplant. Leuk Lymphoma. 2021 12; 62(14):3394-3401. PMID: 34477024.
    Citations:    Fields:    
  9. Stahl M, Epstein-Peterson ZD, Intlekofer AM. Oncogenic Mechanisms and Therapeutic Targeting of Metabolism in Leukemia and Lymphoma. Cold Spring Harb Perspect Med. 2021 07 01; 11(7). PMID: 32816875.
    Citations: 1     Fields:    Translation:Humans
  10. Stahl M, Narendra V, Jee J, Derkach A, Maloy M, Geyer MB, Mato AR, Roeker LE, Tallman MS, Shah GL, Daniyan A, Goldberg AD. Neutropenia in adult acute myeloid leukemia patients represents a powerful risk factor for COVID-19 related mortality. Leuk Lymphoma. 2021 08; 62(8):1940-1948. PMID: 34180767.
    Citations:    Fields:    Translation:HumansCells
  11. Bewersdorf JP, Sheth AH, Vetsa S, Grimshaw A, Giri S, Podoltsev NA, Gowda L, Tamari R, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Outcomes of Allogeneic Hematopoietic Cell Transplantation in Patients With Myelofibrosis-A Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 10; 27(10):873.e1-873.e13. PMID: 34052505.
    Citations:    Fields:    Translation:Humans
  12. Xiao W, Chan A, Waarts MR, Mishra T, Liu Y, Cai SF, Yao J, Gao Q, Bowman RL, Koche RP, Csete IS, DelGaudio NL, Derkach A, Baik J, Yanis S, Famulare CA, Patel M, Arcila ME, Stahl M, Rampal RK, Tallman MS, Zhang Y, Dogan A, Goldberg AD, Roshal M, Levine RL. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. Blood. 2021 03 11; 137(10):1377-1391. PMID: 32871587.
    Citations: 4     Fields:    Translation:HumansCells
  13. Stahl M, Menghrajani K, Derkach A, Chan A, Xiao W, Glass J, King AC, Daniyan AF, Famulare C, Cuello BM, Horvat TZ, Abdel-Wahab O, Levine RL, Viny AD, Stein EM, Cai SF, Roshal M, Tallman MS, Goldberg AD. Clinical and molecular predictors of response and survival following venetoclax therapy in relapsed/refractory AML. Blood Adv. 2021 03 09; 5(5):1552-1564. PMID: 33687434.
    Citations: 4     Fields:    Translation:Humans
  14. Bewersdorf JP, Giri S, Wang R, Williams RT, Tallman MS, Zeidan AM, Stahl M. Venetoclax as monotherapy and in combination with hypomethylating agents or low dose cytarabine in relapsed and treatment refractory acute myeloid leukemia: a systematic review and meta-analysis. Haematologica. 2020 11 01; 105(11):2659-2663. PMID: 33131256.
    Citations: 16     Fields:    Translation:Humans
  15. Cortes J, Podoltsev N, Kantarjian H, Borthakur G, Zeidan AM, Stahl M, Taube T, Fagan N, Rajeswari S, Uy GL. Phase 1 dose escalation trial of volasertib in combination with decitabine in patients with acute myeloid leukemia. Int J Hematol. 2021 Jan; 113(1):92-99. PMID: 32951163.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  16. Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Tallman MS, Rampal RK, Zeidan AM, Stahl M. Interferon alpha therapy in essential thrombocythemia and polycythemia vera-a systematic review and meta-analysis. Leukemia. 2021 06; 35(6):1643-1660. PMID: 32868875.
    Citations: 6     Fields:    Translation:Humans
  17. Bewersdorf JP, Giri S, Tallman MS, Zeidan AM, Stahl M. Leukapheresis for the management of hyperleukocytosis in acute myeloid leukemia-A systematic review and meta-analysis. Transfusion. 2020 10; 60(10):2360-2369. PMID: 32776542.
    Citations: 5     Fields:    Translation:Humans
  18. Zeidan AM, Boddu PC, Patnaik MM, Bewersdorf JP, Stahl M, Rampal RK, Shallis R, Steensma DP, Savona MR, Sekeres MA, Roboz GJ, DeAngelo DJ, Schuh AC, Padron E, Zeidner JF, Walter RB, Onida F, Fathi A, DeZern A, Hobbs G, Stein EM, Vyas P, Wei AH, Bowen DT, Montesinos P, Griffiths EA, Verma AK, Keyzner A, Bar-Natan M, Navada SC, Kremyanskaya M, Goldberg AD, Al-Kali A, Heaney ML, Nazha A, Salman H, Luger S, Pratz KW, Konig H, Komrokji R, Deininger M, Cirici BX, Bhatt VR, Silverman LR, Erba HP, Fenaux P, Platzbecker U, Santini V, Wang ES, Tallman MS, Stone RM, Mascarenhas J. Special considerations in the management of adult patients with acute leukaemias and myeloid neoplasms in the COVID-19 era: recommendations from a panel of international experts. Lancet Haematol. 2020 Aug; 7(8):e601-e612. PMID: 32563283.
    Citations: 22     Fields:    Translation:HumansCellsPHPublic Health
  19. Bewersdorf JP, Giri S, Wang R, Podoltsev N, Williams RT, Rampal RK, Tallman MS, Zeidan AM, Stahl M. Interferon Therapy in Myelofibrosis: Systematic Review and Meta-analysis. Clin Lymphoma Myeloma Leuk. 2020 10; 20(10):e712-e723. PMID: 32669244.
    Citations: 4     Fields:    Translation:Humans
  20. Shallis RM, Stahl M, Bewersdorf JP, Hendrickson JE, Zeidan AM. Leukocytapheresis for patients with acute myeloid leukemia presenting with hyperleukocytosis and leukostasis: a contemporary appraisal of outcomes and benefits. Expert Rev Hematol. 2020 05; 13(5):489-499. PMID: 32248712.
    Citations: 4     Fields:    Translation:Humans
  21. Stahl M, Tallman MS. Late and very late relapses in acute myeloid leukemia (AML). Leuk Lymphoma. 2020 05; 61(5):1010-1011. PMID: 32283963.
    Citations:    Fields:    Translation:Humans
  22. Stahl M, Shallis RM, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukherjee S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Management of hyperleukocytosis and impact of leukapheresis among patients with acute myeloid leukemia (AML) on short- and long-term clinical outcomes: a large, retrospective, multicenter, international study. Leukemia. 2020 12; 34(12):3149-3160. PMID: 32132655.
    Citations: 11     Fields:    Translation:Humans
  23. Shallis RM, Stahl M, Wei W, Montesinos P, Lengline E, Neukirchen J, Bhatt VR, Sekeres MA, Fathi AT, Konig H, Luger S, Khan I, Roboz GJ, Cluzeau T, Martínez-Cuadron D, Raffoux E, Germing U, Umakanthan JM, Mukhereje S, Brunner AM, Miller A, McMahon CM, Ritchie EK, Rodríguez-Veiga R, Itzykson R, Boluda B, Rabian F, Tormo M, Acuña-Cruz E, Rabinovich E, Yoo B, Cano I, Podoltsev NA, Bewersdorf JP, Gore S, Zeidan AM. Patterns of care and clinical outcomes of patients with newly diagnosed acute myeloid leukemia presenting with hyperleukocytosis who do not receive intensive chemotherapy. Leuk Lymphoma. 2020 05; 61(5):1220-1225. PMID: 32100599.
    Citations: 3     Fields:    Translation:Humans
  24. Pine AB, Chokr N, Stahl M, Steensma DP, Sekeres MA, Litzow MR, Luger SM, Stone RM, Greenberg PL, Bejar R, Bewersdorf JP, Gore SD, Zeidan AM. Wide variation in use and interpretation of gene mutation profiling panels among health care providers of patients with myelodysplastic syndromes: results of a large web-based survey. Leuk Lymphoma. 2020 06; 61(6):1455-1464. PMID: 32026740.
    Citations:    Fields:    Translation:Humans
  25. Stahl M, Tallman MS. Outcomes of allogeneic stem cell transplantation for patients with t(6:9) AML- A strong case for allogeneic stem cell transplantation in first complete remission. Br J Haematol. 2020 06; 189(5):806-808. PMID: 31999852.
    Citations:    Fields:    Translation:Humans
  26. Agrawal V, Gbolahan OB, Stahl M, Zeidan AM, Zaid MA, Farag SS, Konig H. Vaccine and Cell-based Therapeutic Approaches in Acute Myeloid Leukemia. Curr Cancer Drug Targets. 2020; 20(7):473-489. PMID: 32357813.
    Citations: 2     Fields:    Translation:HumansAnimalsCells
  27. Stahl M, Tallman MS. Acute promyelocytic leukemia (APL): remaining challenges towards a cure for all. Leuk Lymphoma. 2019 12; 60(13):3107-3115. PMID: 31842650.
    Citations: 12     Fields:    Translation:Humans
  28. Zeidan AM, Hu X, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Bewersdorf JP, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents. Leuk Lymphoma. 2020 02; 61(2):397-408. PMID: 31570040.
    Citations: 5     Fields:    Translation:Humans
  29. Stahl M, Tallman MS. Differentiation syndrome in acute promyelocytic leukaemia. Br J Haematol. 2019 10; 187(2):157-162. PMID: 31410848.
    Citations: 26     Fields:    Translation:Humans
  30. Bewersdorf JP, Stahl M, Zeidan AM. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant. Expert Rev Hematol. 2019 08; 12(8):575-578. PMID: 31225770.
    Citations:    Fields:    Translation:HumansCells
  31. Stahl M, Tallman MS. Antibody-based therapy in acute leukemia - beware the risks. Leuk Lymphoma. 2019 07; 60(7):1608-1609. PMID: 31204877.
    Citations:    Fields:    Translation:Humans
  32. Zeidan AM, Zhu W, Stahl M, Wang R, Huntington SF, Giri S, Podoltsev NA, Gore SD, Ma X, Davidoff AJ. RBC transfusion independence among lower risk MDS patients receiving hypomethylating agents: a population-level analysis. Leuk Lymphoma. 2019 12; 60(13):3181-3187. PMID: 31170846.
    Citations: 3     Fields:    Translation:HumansCells
  33. Stahl M, Bewersdorf JP, Giri S, Wang R, Zeidan AM. Use of immunosuppressive therapy for management of myelodysplastic syndromes: a systematic review and meta-analysis. Haematologica. 2020 01; 105(1):102-111. PMID: 31004015.
    Citations: 12     Fields:    Translation:Humans
  34. Chokr N, Pine AB, Bewersdorf JP, Shallis RM, Stahl M, Zeidan AM. Getting personal with myelodysplastic syndromes: is now the right time? Expert Rev Hematol. 2019 04; 12(4):215-224. PMID: 30977414.
    Citations: 2     Fields:    Translation:HumansAnimals
  35. Stahl M, Goldberg AD. Immune Checkpoint Inhibitors in Acute Myeloid Leukemia: Novel Combinations and Therapeutic Targets. Curr Oncol Rep. 2019 03 23; 21(4):37. PMID: 30904967.
    Citations: 29     Fields:    Translation:HumansCells
  36. Bewersdorf JP, Stahl M, Zeidan AM. Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled. Expert Rev Anticancer Ther. 2019 05; 19(5):393-404. PMID: 30887841.
    Citations: 8     Fields:    Translation:HumansAnimals
  37. Bewersdorf JP, Stahl M, Zeidan AM. Are we witnessing the start of a therapeutic revolution in acute myeloid leukemia? Leuk Lymphoma. 2019 06; 60(6):1354-1369. PMID: 30652518.
    Citations: 11     Fields:    Translation:Humans
  38. Bewersdorf JP, Shallis R, Stahl M, Zeidan AM. Epigenetic therapy combinations in acute myeloid leukemia: what are the options? Ther Adv Hematol. 2019; 10:2040620718816698. PMID: 30719265.
    Citations: 28     
  39. Liu Y, Bewersdorf JP, Stahl M, Zeidan AM. Immunotherapy in acute myeloid leukemia and myelodysplastic syndromes: The dawn of a new era? Blood Rev. 2019 03; 34:67-83. PMID: 30553527.
    Citations: 32     Fields:    Translation:HumansAnimals
  40. Shallis RM, Chokr N, Stahl M, Pine AB, Zeidan AM. Immunosuppressive therapy in myelodysplastic syndromes: a borrowed therapy in search of the right place. Expert Rev Hematol. 2018 09; 11(9):715-726. PMID: 30024293.
    Citations: 8     Fields:    Translation:Humans
  41. Stahl M, DeVeaux M, de Witte T, Neukirchen J, Sekeres MA, Brunner AM, Roboz GJ, Steensma DP, Bhatt VR, Platzbecker U, Cluzeau T, Prata PH, Itzykson R, Fenaux P, Fathi AT, Smith A, Germing U, Ritchie EK, Verma V, Nazha A, Maciejewski JP, Podoltsev NA, Prebet T, Santini V, Gore SD, Komrokji RS, Zeidan AM. The use of immunosuppressive therapy in MDS: clinical outcomes and their predictors in a large international patient cohort. Blood Adv. 2018 07 24; 2(14):1765-1772. PMID: 30037803.
    Citations: 33     Fields:    Translation:HumansCTClinical Trials
  42. Kim TK, DeVeaux M, Stahl M, Perreault S, Isufi I, Cooper D, Foss F, Shlomchik W, Zelterman D, Zeidan AM, Seropian S. Long-term follow-up of a single institution pilot study of sirolimus, tacrolimus, and short course methotrexate for graft versus host disease prophylaxis in mismatched unrelated donor allogeneic stem cell transplantation. Ann Hematol. 2019 Jan; 98(1):237-240. PMID: 30027436.
    Citations: 1     Fields:    Translation:HumansCTClinical Trials
  43. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard J, Podoltsev NA, Brunner A, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua J, Serrano J, Gore SD, Zeidan AM. Performance of the Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) score in predicting survival benefit with hypomethylating agent use in patients with relapsed or refractory acute myeloid leukemia. Leuk Lymphoma. 2019 01; 60(1):246-249. PMID: 29963936.
    Citations:    Fields:    Translation:Humans
  44. Zeidan AM, Stahl M, DeVeaux M, Giri S, Huntington S, Podoltsev N, Wang R, Ma X, Davidoff AJ, Gore SD. Counseling patients with higher-risk MDS regarding survival with azacitidine therapy: are we using realistic estimates? Blood Cancer J. 2018 06 11; 8(6):55. PMID: 29891916.
    Citations: 7     Fields:    Translation:Humans
  45. Stahl M, Zeidan AM. Improved JAK Inhibition in Myelofibrosis-The Long Road Ahead. JAMA Oncol. 2018 05 01; 4(5):659-660. PMID: 29522105.
    Citations: 1     Fields:    Translation:Humans
  46. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Barnard JD, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Fathi AT, Roboz GJ, Fenaux P, Litzow MR, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Germing U, Bergua JM, Serrano J, Gore SD, Zeidan AM. Hypomethylating agents in relapsed and refractory AML: outcomes and their predictors in a large international patient cohort. Blood Adv. 2018 04 24; 2(8):923-932. PMID: 29685952.
    Citations: 30     Fields:    Translation:HumansCells
  47. Stahl M, Pine A, Hendrickson JE, Litzow MR, Luger SM, Stone RM, Erba HP, Kim TK, Sekeres MA, Steensma DP, Komrokji RS, Gore SD, Zeidan AM. Beliefs and practice patterns in hyperleukocytosis management in acute myeloid leukemia: a large U.S. web-based survey. Leuk Lymphoma. 2018 11; 59(11):2723-2726. PMID: 29667455.
    Citations: 3     Fields:    Translation:Humans
  48. Uy N, Nadeau M, Stahl M, Zeidan AM. Inotuzumab ozogamicin in the treatment of relapsed/refractory acute B cell lymphoblastic leukemia. J Blood Med. 2018; 9:67-74. PMID: 29713210.
    Citations: 5     
  49. Stahl M, DeVeaux M, Montesinos P, Itzykson R, Ritchie EK, Sekeres MA, Majhail N, Barnard J, Podoltsev NA, Brunner AM, Komrokji RS, Bhatt VR, Al-Kali A, Cluzeau T, Santini V, Roboz GJ, Fenaux P, Litzow M, Fathi AT, Perreault S, Kim TK, Prebet T, Vey N, Verma V, Kobbe G, Bergua J, Serrano J, Gore SD, Zeidan AM. Allogeneic Hematopoietic Stem Cell Transplantation Following the Use of Hypomethylating Agents among Patients with Relapsed or Refractory AML: Findings from an International Retrospective Study. Biol Blood Marrow Transplant. 2018 08; 24(8):1754-1758. PMID: 29649620.
    Citations:    Fields:    Translation:Humans
  50. Stahl M, Lu BY, Kim TK, Zeidan AM. Novel Therapies for Acute Myeloid Leukemia: Are We Finally Breaking the Deadlock? Target Oncol. 2017 08; 12(4):413-447. PMID: 28664386.
    Citations: 8     Fields:    Translation:Humans
  51. Zeidan AM, Stahl M, Sekeres MA, Steensma DP, Komrokji RS, Gore SD. A call for action: Increasing enrollment of untreated patients with higher-risk myelodysplastic syndromes in first-line clinical trials. Cancer. 2017 Oct 01; 123(19):3662-3672. PMID: 28759108.
    Citations: 12     Fields:    Translation:Humans
  52. Li AW, Yin ES, Stahl M, Kim TK, Panse G, Zeidan AM, Leventhal JS. The skin as a window to the blood: Cutaneous manifestations of myeloid malignancies. Blood Rev. 2017 11; 31(6):370-388. PMID: 28732587.
    Citations: 5     Fields:    Translation:HumansAnimals
  53. Stahl M, Zeidan AM. Management of myelofibrosis: JAK inhibition and beyond. Expert Rev Hematol. 2017 05; 10(5):459-477. PMID: 28395559.
    Citations: 4     Fields:    Translation:Humans
  54. Stahl M, Zeidan AM. Management of lower-risk myelodysplastic syndromes without del5q: current approach and future trends. Expert Rev Hematol. 2017 Apr; 10(4):345-364. PMID: 28277851.
    Citations: 5     Fields:    Translation:HumansCells
  55. Weed J, Ko C, Stahl M, Much M, Witt D, Zeidan AM, Leventhal J. Reactive granulomatous dermatitis presenting as subcutaneous nodules and cords in a patient with advanced myelodysplastic syndrome. Ann Hematol. 2017 06; 96(6):1037-1039. PMID: 28220192.
    Citations: 2     Fields:    Translation:HumansCells
  56. Stahl M, Zeidan AM. Lenalidomide use in myelodysplastic syndromes: Insights into the biologic mechanisms and clinical applications. Cancer. 2017 05 15; 123(10):1703-1713. PMID: 28192601.
    Citations: 14     Fields:    Translation:HumansCells
  57. Stahl M, Zeidan AM. Hypomethylating agents in combination with histone deacetylase inhibitors in higher risk myelodysplastic syndromes: Is there a light at the end of the tunnel? Cancer. 2017 05 15; 123(6):911-914. PMID: 28094843.
    Citations: 7     Fields:    Translation:HumansCells
  58. Stahl M, Kim TK, Zeidan AM. Update on acute myeloid leukemia stem cells: New discoveries and therapeutic opportunities. World J Stem Cells. 2016 Oct 26; 8(10):316-331. PMID: 27822339.
    Citations: 9     
  59. Stahl M, Kohrman N, Gore SD, Kim TK, Zeidan AM, Prebet T. Epigenetics in Cancer: A Hematological Perspective. PLoS Genet. 2016 Oct; 12(10):e1006193. PMID: 27723796.
    Citations: 30     Fields:    Translation:HumansCells
  60. Podoltsev NA, Stahl M, Zeidan AM, Gore SD. Selecting initial treatment of acute myeloid leukaemia in older adults. Blood Rev. 2017 03; 31(2):43-62. PMID: 27745715.
    Citations: 32     Fields:    Translation:Humans
  61. Zeidan AM, Stahl M, Komrokji R. Emerging biological therapies for the treatment of myelodysplastic syndromes. Expert Opin Emerg Drugs. 2016 Sep; 21(3):283-300. PMID: 27486848.
    Citations: 5     Fields:    Translation:HumansAnimalsCells
  62. Kim TK, Xu ML, Podoltsev NA, Prebet T, Barbarotta L, Amin K, Kasberg S, Roche K, Stahl M, Gore SD, Zeidan AM. Single agent blinatumumab as frontline therapy for an 85-year-old patient with B cell precursor acute lymphoblastic leukemia. Ann Hematol. 2016 Oct; 95(11):1895-8. PMID: 27468851.
    Citations:    Fields:    Translation:Humans
  63. Suozzi KC, Stahl M, Ko CJ, Chiang A, Gettinger SN, Siegel MD, Bunick CG. Immune-related sarcoidosis observed in combination ipilimumab and nivolumab therapy. JAAD Case Rep. 2016 May; 2(3):264-8. PMID: 27486590.
    Citations: 23     
  64. Stahl M, Gedrich R, Peck R, LaVallee T, Eder JP. Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitors. Immunotherapy. 2016 06; 8(7):767-74. PMID: 27349976.
    Citations: 3     Fields:    Translation:HumansAnimalsCells
  65. Stahl M, Mohareb AM, Lee AI, Federman DG, Siddon AJ, Spelman J. Multi-system complications of hypereosinophilia. Am J Hematol. 2016 Jun; 91(4):444-7. PMID: 26700720.
    Citations:    Fields:    Translation:Humans
  66. Stahl M, Xu ML, Steensma DP, Rampal R, Much M, Zeidan AM. Clinical response to ruxolitinib in CSF3R T618-mutated chronic neutrophilic leukemia. Ann Hematol. 2016 Jun; 95(7):1197-200. PMID: 27068405.
    Citations: 14     Fields:    Translation:Humans
  67. Stahl M, Gore SD, Vey N, Prebet T. Lost in translation? Ten years of development of histone deacetylase inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Expert Opin Investig Drugs. 2016; 25(3):307-17. PMID: 26807602.
    Citations: 14     Fields:    Translation:HumansAnimals
  68. Stahl K, Stahl M, de Jonge HR, Forrest JN. ANP and CNP activate CFTR expressed in Xenopus laevis oocytes by direct activation of PKA. J Recept Signal Transduct Res. 2015; 35(5):493-504. PMID: 26016495.
    Citations: 6     Fields:    Translation:AnimalsCells
  69. Stahl M, Stahl K, Brubacher MB, Forrest JN. Divergent CFTR orthologs respond differently to the channel inhibitors CFTRinh-172, glibenclamide, and GlyH-101. Am J Physiol Cell Physiol. 2012 Jan 01; 302(1):C67-76. PMID: 21940661.
    Citations: 21     Fields:    Translation:HumansAnimalsCells
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Stahl's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (226)
Explore
_
Co-Authors (7)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.